Khang & Khang LLP (the "Firm") announces the filing of a securities class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Investors who purchased or otherwise acquired shares between June 17, 2015 and August 10, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm in advance of the October 24, 2017 lead plaintiff motion deadline. If you purchased Dr. Reddy's shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org. There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well. According to the Complaint, throughout the Class Period, Dr. Reddy's made false and/or misleading statements, and/or failed to disclose, that the Company lacked an effective corporate quality system; and thus, its public statements were materially false and misleading at all relevant times. On August 10, 2017, Dr. Reddy's disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant. When this news was announced, shares of Dr. Reddy's declined in value materially, which caused investors harm according to the Complaint. If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esquire, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at email@example.com. This press release may constitute Attorney Advertising in some jurisdictions.